Stocks
Lilly Surges Ahead of Merck with Blockbuster Drug Sales
Eli Lilly's quarterly revenue soared by 47.7% in Q2 2026, driven primarily by strong sales of its diabetes and obesity treatments Mounjaro and Zepbound.
The company is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo, further solidifying its position as a leader in the health sector.
In contrast, Merck's revenue growth was more modest at 5%, with KEYTRUDA's sales plateauing and the company facing a significant patent cliff.
Lilly's robust pipeline and raised guidance make it a more durable growth story through 2030, while Merck may appeal to value investors due to its lower valuation and dividend yield.